Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT04974216
Title Study of Tafasitamab and Lenalinomide Associated to Rituximab in Frontline Diffuse Large B-Cell Lymphoma Patients of 80 y/o or Older
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors The Lymphoma Academic Research Organisation
Indications

diffuse large B-cell lymphoma

follicular lymphoma

B-cell lymphoma

Therapies

Lenalidomide + Rituximab + Tafasitamab-cxix

Age Groups: senior
Covered Countries FRA | BEL


No variant requirements are available.